Structure-based Drug Design For Neuroprotection From Traditional Chinese Medicine
Funder
National Health and Medical Research Council
Funding Amount
$245,968.00
Summary
In the proposed research, three novo approaches for drug discovery will be explored: 1) The important neurodegenerative disease relevant protein JNK3 crystals will be used as the probe to fish out the potential inhibitors from Traditional Chinese Medicine (TCM); 2) Instead of individual drug components, the mixture of TCM will be used directly; 3) The composition of a TCM library are not randomly chosen but have been used in China for hundreds to thousands of years in curing neurodegenerative di ....In the proposed research, three novo approaches for drug discovery will be explored: 1) The important neurodegenerative disease relevant protein JNK3 crystals will be used as the probe to fish out the potential inhibitors from Traditional Chinese Medicine (TCM); 2) Instead of individual drug components, the mixture of TCM will be used directly; 3) The composition of a TCM library are not randomly chosen but have been used in China for hundreds to thousands of years in curing neurodegenerative disease.Read moreRead less
Lipophilic Iron Chelators As Potential Therapeutic Agents In Parkinson's Disease
Funder
National Health and Medical Research Council
Funding Amount
$616,537.00
Summary
The impaired coordination and tremors experienced by the 64,000 Australians with Parkinson’s disease make managing life at work and home difficult. With 240,000 Australians projected to be living with Parkinson’s disease by 2033, the discovery of agents that slow or stop disease progression is urgent. Iron in the brain has been implicated in Parkinson’s disease. In this project, the performance of new low toxicity agents in altering brain iron distribution will be studied as potential drugs for ....The impaired coordination and tremors experienced by the 64,000 Australians with Parkinson’s disease make managing life at work and home difficult. With 240,000 Australians projected to be living with Parkinson’s disease by 2033, the discovery of agents that slow or stop disease progression is urgent. Iron in the brain has been implicated in Parkinson’s disease. In this project, the performance of new low toxicity agents in altering brain iron distribution will be studied as potential drugs for Parkinson’s disease.Read moreRead less
Inhibitory Neurotransmitter Receptors As Therapeutic Targets For Chronic Pain And Anxiety Disorders
Funder
National Health and Medical Research Council
Funding Amount
$763,409.00
Summary
There are currently few effective long-term treatments for chronic pain and anxiety disorders. Here we propose to develop innovative therapies for both of these debilitating neurological disorders. In addition, we plan to improve our current understanding of how these disorders occur in the first place. This may identify novel potential therapeutic strategies for treating pain, anxiety and a host of other neurological disorders.
A Novel Mechanism For Therapeutically Modulating Neurotransmitter-activated Ion Channels
Funder
National Health and Medical Research Council
Funding Amount
$667,529.00
Summary
This project aims to elucidate the mechanisms by which macrocyclic lactones bind to brain ion channel receptors. This will reveal fundamental new insights into the operation of these receptors and will have important implications for the design of novel treatments for a variety of central nervous system disorders.
Integrated Analysis Of Genome, Epigenome, And Transcriptome Data In Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$417,511.00
Summary
Schizophrenia is a severe psychiatric disorder with a diverse range of symptoms. While the cause is unknown, it is thought to develop from a combination of genetic, epigenetic and environmental risk factors. This study will use genome wide approaches to investigate the relationship between genetic/epigenetic modification of DNA and gene expression in schizophrenia. This study could provide an integrated understanding of the neuropathology of schizophrenia and ultimately lead to better treatment.
‘Chemobrain’: Neuroimmunological Consequences Of Chemotherapy-induced Mucositis And Opioid Palliation In Development Of The Condition
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Approximately 46% of cancer patients receiving chemotherapy will experience cognitive impairment. The development of this condition may be linked to another common gut side-effect of chemotherapy- mucositis. The treatment of mucositis pain by potent painkillers called opioids may also increase the risk of cognitive change. This project will determine the nervous system changes occurring in mucositis to identify targets for drug intervention to prevent development of cognitive decline.
Interleukin-6 -gp130 Signaling And Actions In The CNS
Funder
National Health and Medical Research Council
Funding Amount
$549,092.00
Summary
Interleukin-6 (IL-6) is a member of a family of cytokine proteins that may be causative factors in many neurological disorders where they are involved in diverse processes including inflammation, neuronal injury and repair. In this project we will study how IL-6 affects the brain to bring about these outcomes. The results of this work will advance our understanding of how members of this cytokine family function and how they contribute to neurological disease.
Defining Reciprocal Neural Circuits That Regulate Appetite And Memory
Funder
National Health and Medical Research Council
Funding Amount
$341,935.00
Summary
How we remember meals influences how much we eat at later time points. This kind of memory likely comes from both the traditional brain areas associated with memory formation, and from areas associated with regulating appetite. How these two brain regions work together to help animals remember what they ate, where they found it, and whether they liked it is not known. This project investigates how these memories are formed and how they are used by animals to make decisions about future meals.
Development Of Pthaladyn-based Dynamin I-selective Inhibitors For Treatment Of Epilepsy
Funder
National Health and Medical Research Council
Funding Amount
$564,310.00
Summary
About 1% of the World�s population suffers from epilepsy; 30% fail to respond to anti-epileptic drugs (AED). Current AED development pathways have changed little in the past 20 years with the majority of current AEDs dampening the release of crucial chemical signals 24/7. Our new drugs, which inhibit a protein called dynamin, are only recruited at the onset of a seizure. Our approach will significantly enhance the day to day lives of those afflicted by epilepsy.
Closed-loop Deep Brain Stimulation: Optimising Treatment Of Parkinson’s Disease Using Adaptive Stimulation
Funder
National Health and Medical Research Council
Funding Amount
$726,177.00
Summary
Deep brain stimulation is an established therapy for Parkinson's disease when patients’ symptoms cannot be controlled adequately using medication. Although deep brain stimulation usually improves quality of life significantly, existing devices have shortcomings that often result in poor symptom alleviation and/or undesirable side-effects. This project is aimed at developing an innovative system that automatically adjusts stimulation according to the continually fluctuating needs of each patient.